WO2001012812A3 - Baff receptor (bcma), an immunoregulatory agent - Google Patents

Baff receptor (bcma), an immunoregulatory agent Download PDF

Info

Publication number
WO2001012812A3
WO2001012812A3 PCT/US2000/022507 US0022507W WO0112812A3 WO 2001012812 A3 WO2001012812 A3 WO 2001012812A3 US 0022507 W US0022507 W US 0022507W WO 0112812 A3 WO0112812 A3 WO 0112812A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcma
baff receptor
immunoregulatory agent
baff
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/022507
Other languages
French (fr)
Other versions
WO2001012812A2 (en
Inventor
Fabienne Mackay
Jeffrey Browning
Christine Ambrose
Jurg Tschopp
Pascal Schneider
Jeffrey Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27386828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001012812(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EEP200200071A priority Critical patent/EE05673B1/en
Priority to EA200200261A priority patent/EA004635B1/en
Priority to AU69112/00A priority patent/AU780240B2/en
Priority to IL14808900A priority patent/IL148089A0/en
Priority to SK50017-2015A priority patent/SK288603B6/en
Priority to EP00957502.8A priority patent/EP1210425B2/en
Priority to BRPI0013391A priority patent/BRPI0013391B8/en
Priority to DK00957502.8T priority patent/DK1210425T4/en
Priority to BR0013391-4A priority patent/BR0013391A/en
Priority to DE60034579.3T priority patent/DE60034579T3/en
Priority to JP2001516900A priority patent/JP4787439B2/en
Priority to MXPA02001665A priority patent/MXPA02001665A/en
Priority to NZ517782A priority patent/NZ517782A/en
Priority to HU1100145A priority patent/HU230583B1/en
Priority to CA2383154A priority patent/CA2383154C/en
Priority to UA2002032076A priority patent/UA75049C2/en
Priority to SK229-2002A priority patent/SK288287B6/en
Application filed by Biogen Inc filed Critical Biogen Inc
Priority to HK02105250.2A priority patent/HK1043608B/en
Priority to HU0203084A priority patent/HU227008B1/en
Publication of WO2001012812A2 publication Critical patent/WO2001012812A2/en
Publication of WO2001012812A3 publication Critical patent/WO2001012812A3/en
Priority to IL148089A priority patent/IL148089A/en
Priority to US10/077,438 priority patent/US7083785B2/en
Priority to IS6273A priority patent/IS2955B/en
Priority to US10/077,137 priority patent/US7691804B2/en
Anticipated expiration legal-status Critical
Priority to NO20020789A priority patent/NO331410B1/en
Priority to BG106519A priority patent/BG106519A/en
Priority to US12/500,909 priority patent/US20100040627A1/en
Priority to NO20111232A priority patent/NO344346B1/en
Priority to US13/401,610 priority patent/US8828669B2/en
Priority to IL230961A priority patent/IL230961A/en
Priority to US14/452,870 priority patent/US9650430B2/en
Priority to US15/595,733 priority patent/US10494416B2/en
Priority to US16/654,244 priority patent/US20200095305A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
PCT/US2000/022507 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent Ceased WO2001012812A2 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
EP00957502.8A EP1210425B2 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent
HK02105250.2A HK1043608B (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent
AU69112/00A AU780240B2 (en) 1999-08-17 2000-08-16 BAFF receptor (BCMA), an immunoregulatory agent
IL14808900A IL148089A0 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunorgulatory agent
SK50017-2015A SK288603B6 (en) 1999-08-17 2000-08-16 Polypeptide and antibody binding to polypeptide
MXPA02001665A MXPA02001665A (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent.
BRPI0013391A BRPI0013391B8 (en) 1999-08-17 2000-08-16 use of bcma polypeptides in the preparation of a pharmaceutical composition to treat an autoimmune disease or a b-cell lymphoproliferative disorder
DK00957502.8T DK1210425T4 (en) 1999-08-17 2000-08-16 BAFF receptor (BCMA), an immunoregulatory agent
BR0013391-4A BR0013391A (en) 1999-08-17 2000-08-16 Use of the baff receptor (bcma) as an immunoregulatory agent
DE60034579.3T DE60034579T3 (en) 1999-08-17 2000-08-16 BAFF RECEPTOR (BCMA), AN IMMUNO-REGULATORY MEDIUM
JP2001516900A JP4787439B2 (en) 1999-08-17 2000-08-16 BAFF receptor (BCMA), an immune regulator
EA200200261A EA004635B1 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent
NZ517782A NZ517782A (en) 1999-08-17 2000-08-16 A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
HU1100145A HU230583B1 (en) 1999-08-17 2000-08-16 Uses of baff-receptor (bcma) as an immunoregulatory agent
CA2383154A CA2383154C (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent
UA2002032076A UA75049C2 (en) 1999-08-17 2000-08-16 A pharmaceutical composition containing polypeptide , which represents protein factor of ripening B-cells (ВСМА) BEING tied with the factor of activating B-cells (BAFF), A method FOR inhibiting B-cells growth, a method FOR THE treatment of autoimmune disease, a method FOR THE treatment of hypertension, a method FOR inhibiting inflammation and method FOR modulation of immune response by mammal USING ВСМА.
SK229-2002A SK288287B6 (en) 1999-08-17 2000-08-16 Antibody directed against SEQ ID NO:1 or polypeptide comprising it, and use thereof
EEP200200071A EE05673B1 (en) 1999-08-17 2000-08-16 BAFF receptor (BCMA), an immunoregulatory agent
HU0203084A HU227008B1 (en) 1999-08-17 2000-08-16 Use of baff receptor (bcma) as an immunoregulatory agent
IL148089A IL148089A (en) 1999-08-17 2002-02-10 Use of an antibody directed against bcma for the preparation of a medicament for treating an autoimmune disorder, a b-cell lymphoproliferative disorder, or inflammation
IS6273A IS2955B (en) 1999-08-17 2002-02-15 BAFF receptor (BCMA), immunosuppressant
US10/077,137 US7691804B2 (en) 1999-08-17 2002-02-15 BAFF receptor (BCMA), an immunoregulatory agent
US10/077,438 US7083785B2 (en) 1999-08-17 2002-02-15 Methods of treatment by administering an anti-BCMA antibody
NO20020789A NO331410B1 (en) 1999-08-17 2002-02-18 Antibody against BAFF receptor (BCMA) as an immunoregulatory agent
BG106519A BG106519A (en) 1999-08-17 2002-03-14 Baff receptor (bcma), an immunoregulatory agent
US12/500,909 US20100040627A1 (en) 1999-08-17 2009-07-10 Baff receptor (bcma), an immunoregulatory agent
NO20111232A NO344346B1 (en) 1999-08-17 2011-09-12 BAFF receptor (BCMA), an immunoregulatory agent
US13/401,610 US8828669B2 (en) 1999-08-17 2012-02-21 Methods of screening for a compound that inhibits the interaction between BAFF and BCMA
IL230961A IL230961A (en) 1999-08-17 2014-02-13 Baff receptor (bcma), an immunoregulatory agent
US14/452,870 US9650430B2 (en) 1999-08-17 2014-08-06 Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)
US15/595,733 US10494416B2 (en) 1999-08-17 2017-05-15 Methods of modulating immune responses using BCMA polypeptide
US16/654,244 US20200095305A1 (en) 1999-08-17 2019-10-16 Methods of modulating immune responses using bcma polypeptide

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14937899P 1999-08-17 1999-08-17
US60/149,378 1999-08-17
US18168400P 2000-02-11 2000-02-11
US60/181,684 2000-02-11
US18353600P 2000-02-18 2000-02-18
US60/183,536 2000-02-18

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/077,438 Continuation-In-Part US7083785B2 (en) 1999-08-17 2002-02-15 Methods of treatment by administering an anti-BCMA antibody
US10/077,137 Continuation US7691804B2 (en) 1999-08-17 2002-02-15 BAFF receptor (BCMA), an immunoregulatory agent
US10/077,137 Continuation-In-Part US7691804B2 (en) 1999-08-17 2002-02-15 BAFF receptor (BCMA), an immunoregulatory agent

Publications (2)

Publication Number Publication Date
WO2001012812A2 WO2001012812A2 (en) 2001-02-22
WO2001012812A3 true WO2001012812A3 (en) 2001-09-07

Family

ID=27386828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022507 Ceased WO2001012812A2 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent

Country Status (29)

Country Link
US (7) US7691804B2 (en)
EP (3) EP1210425B2 (en)
JP (4) JP4787439B2 (en)
KR (2) KR100897082B1 (en)
CN (1) CN100447244C (en)
AT (1) ATE360693T1 (en)
AU (1) AU780240B2 (en)
BG (1) BG106519A (en)
BR (2) BRPI0013391B8 (en)
CA (1) CA2383154C (en)
CZ (1) CZ300364B6 (en)
DE (1) DE60034579T3 (en)
DK (1) DK1210425T4 (en)
EA (1) EA004635B1 (en)
EE (1) EE05673B1 (en)
GE (1) GEP20053685B (en)
HK (1) HK1043608B (en)
HU (3) HU230583B1 (en)
IL (3) IL148089A0 (en)
IS (1) IS2955B (en)
MX (1) MXPA02001665A (en)
NO (2) NO331410B1 (en)
NZ (1) NZ517782A (en)
PL (2) PL211786B1 (en)
RS (1) RS51157B (en)
SK (2) SK288287B6 (en)
TR (1) TR200201063T2 (en)
UA (1) UA75049C2 (en)
WO (1) WO2001012812A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
WO2000068378A1 (en) 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
UA75049C2 (en) * 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. A pharmaceutical composition containing polypeptide , which represents protein factor of ripening B-cells (ВСМА) BEING tied with the factor of activating B-cells (BAFF), A method FOR inhibiting B-cells growth, a method FOR THE treatment of autoimmune disease, a method FOR THE treatment of hypertension, a method FOR inhibiting inflammation and method FOR modulation of immune response by mammal USING ВСМА.
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) * 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
DE10049010A1 (en) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin polycation / DNA complexes for the systemic therapy of tumor diseases with cytotoxic proteins
BRPI0209933B8 (en) 2001-05-24 2021-05-25 Zymogenetics Inc fusion protein, and, nucleic acid molecule
BR0211614A (en) * 2001-08-03 2006-10-31 Genentech Inc tacis and br3 polypeptide and their uses
AU2003221256A1 (en) * 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
CN1692127A (en) * 2002-07-25 2005-11-02 健泰科生物技术公司 TACI antibodies and uses thereof
WO2004094620A2 (en) * 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
PL1631313T3 (en) * 2003-06-05 2015-08-31 Genentech Inc Combination therapy for b cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
AU2004285455A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for BAFF antagonists
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CA2585927A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
WO2006067210A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
AU2006209237B2 (en) * 2005-01-28 2010-06-24 Biogen Ma Inc. Use of BAFF to treat Th2-mediated conditions
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EA015860B1 (en) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Methods for treatment of autoimmune diseases using neutrokine-alpha antagonist
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
JP2009537563A (en) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Methods for treating autoimmune diseases using TACI fusion molecules
KR101314369B1 (en) * 2008-07-17 2013-10-10 노파르티스 아게 Compositions and methods of use for therapeutic antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN101781680B (en) * 2009-10-19 2012-05-09 南通大学附属医院 Method for Determining Factors Influencing Human BAFF-R Gene Promoter Activity
WO2011108008A2 (en) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
UA112434C2 (en) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед ANTIGENCY BINDING SPECIFICALLY Binds to ALL
CA2833820C (en) * 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
KR20140119777A (en) 2012-01-31 2014-10-10 제넨테크, 인크. Anti-ig-e m1' antibodies and methods using same
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
CN106459990B (en) 2014-02-07 2021-06-01 麦克马斯特大学 Trifunctional T cell antigen conjugate and preparation method and use thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
TWI750110B (en) 2014-07-21 2021-12-21 瑞士商諾華公司 Treatment of cancer using humanized anti- bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
KR20250067191A (en) 2014-09-17 2025-05-14 노파르티스 아게 Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
KR20240135036A (en) * 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 Antibodies targeting b-cell maturation antigen and methods of use
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PL3988117T3 (en) 2015-04-13 2025-03-10 Pfizer Inc. Therapeutic antibodies and their uses
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN116041514A (en) 2016-06-06 2023-05-02 希望之城 Antibody to BAFF-R and use thereof
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
FI4050034T3 (en) 2016-09-14 2024-06-10 Teneoone Inc Cd3 binding antibodies
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110582509A (en) 2017-01-31 2019-12-17 诺华股份有限公司 Cancer treatment with multispecific chimeric T cell receptor proteins
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2019013514A (en) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology.
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
JP7585034B2 (en) 2017-10-18 2024-11-18 ノバルティス アーゲー Compositions and methods for selective protein degradation
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
JP7447006B2 (en) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Chimeric antigen receptor specific for B cell maturation antigen (BCMA)
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
BR112020010579A2 (en) 2017-11-30 2020-11-10 Novartis Ag bcma targeting chimeric antigen receptor and uses thereof
TW201930591A (en) 2018-01-08 2019-08-01 瑞士商諾華公司 Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US12227763B2 (en) 2018-05-11 2025-02-18 Crispr Therapeutics Ag Methods and compositions for treating cancer
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
UY38251A (en) 2018-06-01 2019-12-31 Novartis Ag BINDING MOLECULES AGAINST BCMA AND USES OF THEM
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MD4324851T2 (en) 2018-07-19 2025-12-31 Regeneron Pharma Chimeric antigen receptors with bcma specificity and uses thereof
TWI838389B (en) 2018-07-19 2024-04-11 美商再生元醫藥公司 BISPECIFIC ANTI-BCMAxANTI-CD3 ANTIBODIES AND USES THEREOF
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20210113169A (en) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Treatment method using chimeric antigen receptor specific for Β cell maturation antigen
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113490528B (en) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (en) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T-cell-associated cancer cells and uses thereof
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
JP7776987B2 (en) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Heavy Chain Antibodies that Bind PSMA
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
PE20220568A1 (en) 2019-05-21 2022-04-20 Novartis Ag CD19 BINDING MOLECULES AND USES THEREOF
CN114206927B (en) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 Multispecific heavy chain antibodies that bind to CD22 and CD3
JP2022539248A (en) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター Recombinant AD35 vectors and related gene therapy improvements
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
MX2022007759A (en) 2019-12-20 2022-07-19 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome.
CN116234829A (en) 2020-01-03 2023-06-06 马伦戈治疗公司 Anti-TCR antibody molecules and uses thereof
KR20220147109A (en) 2020-02-27 2022-11-02 노파르티스 아게 Methods for making chimeric antigen receptor-expressing cells
KR20220146530A (en) 2020-02-27 2022-11-01 노파르티스 아게 Methods of Making Chimeric Antigen Receptor-Expressing Cells
AU2021263448B2 (en) 2020-04-29 2026-02-05 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (en) 2020-06-23 2023-04-04 诺华股份有限公司 Dosage regimens comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
IL299827B1 (en) 2020-07-15 2026-04-01 Cerebral Therapeutics Inc Medical system including two access ports
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN116406371A (en) * 2020-08-12 2023-07-07 斯坦福大学托管董事会 sBCMA variant and its Fc fusion protein
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
AU2022327178A1 (en) 2021-08-11 2024-03-28 Akso Biopharmaceutical, Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
JP2024531364A (en) 2021-08-20 2024-08-29 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN120112650A (en) 2022-10-26 2025-06-06 诺华股份有限公司 Lentiviral preparations
JP2026510999A (en) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． CD19/CD38 multispecific antibody
CN120981456A (en) 2023-05-24 2025-11-18 金橘生物科技公司 Heterocyclic compounds and their uses
WO2025170844A1 (en) * 2024-02-05 2025-08-14 Board Of Regents, The University Of Texas System Chimeric polypeptides and methods of use
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein
WO1999012965A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. April- a novel protein with growth effects
WO2000043032A2 (en) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
DK0897390T3 (en) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumor necrosis factor delta and epsilon
ES2248823T5 (en) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. ALPHA NEUTROQUINE.
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EP0975754B2 (en) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
JP2002517977A (en) 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド NTN-2 member of the TNF ligand family
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012963A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
DE69921718T2 (en) * 1998-04-01 2005-12-22 Solvay Solexis, Inc., Wilmington Compatible blends of polyvinylidene fluoride and aromatic polyimide
AU1467000A (en) 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
DE60043626D1 (en) † 1999-01-07 2010-02-11 Zymogenetics Inc Method for the therapeutic use of soluble receptors BR43X2
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU3380200A (en) 1999-02-24 2000-09-14 General Hospital Corporation, The Method for cloning signal transduction intermediates
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
UA75049C2 (en) * 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. A pharmaceutical composition containing polypeptide , which represents protein factor of ripening B-cells (ВСМА) BEING tied with the factor of activating B-cells (BAFF), A method FOR inhibiting B-cells growth, a method FOR THE treatment of autoimmune disease, a method FOR THE treatment of hypertension, a method FOR inhibiting inflammation and method FOR modulation of immune response by mammal USING ВСМА.
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
JP2003521931A (en) 2000-02-11 2003-07-22 バイオジェン インコーポレイテッド Heterologous polypeptides of the TNF family
CA2396793A1 (en) † 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
EP1309718A4 (en) 2000-08-15 2004-08-25 Human Genome Sciences Inc NEUTROKIN-ALPHA AND SPLICE VARIANTS FROM NEUTROKIN-ALPHA
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
US7083735B2 (en) 2003-09-03 2006-08-01 Laing David A High debris content strainer
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
FR3005792B1 (en) 2013-05-16 2017-12-29 Parknplug METHOD FOR DYNAMICALLY PREDICTIVE MANAGEMENT OF ELECTRICAL BATTERY RECHARGING

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein
WO1999012965A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. April- a novel protein with growth effects
WO2000043032A2 (en) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JANE A. GROSS ET AL.: "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease", NATURE, vol. 404, no. 6781, 27 April 2000 (2000-04-27), LONDON GB, pages 995 - 999, XP002140939 *
JEFFREY S. THOMPSON ET AL.: "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, no. 1, 3 July 2000 (2000-07-03), pages 129 - 135, XP002156772 *
JEFFREY THOMPSON ET AL.: "BAFF interacts with the orphan receptor, BCMA", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 51, June 2000 (2000-06-01), pages 65, XP000971932 *
MARIE-PIERRE GRAS ET AL.: "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes", INTERNATIONAL IMMUNOLOGY, vol. 7, no. 7, July 1995 (1995-07-01), pages 1093 - 1106, XP000971907 *
PASCAL SCHNEIDER ET AL.: "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409 *
Y. LAÂBI ET AL.: "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma", EMBO JOURNAL., vol. 11, 1992, OXFORD UNIVERSITY PRESS, SURREY., GB, pages 3897 - 3904, XP002156771, ISSN: 0261-4189 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Also Published As

Publication number Publication date
EP1210425A2 (en) 2002-06-05
IL148089A (en) 2015-03-31
IS2955B (en) 2016-12-15
IL230961A (en) 2016-06-30
HK1043608B (en) 2007-12-07
EP1806143A2 (en) 2007-07-11
JP2014037434A (en) 2014-02-27
NO344346B1 (en) 2019-11-11
NO331410B1 (en) 2011-12-19
HU227008B1 (en) 2010-04-28
EE200200071A (en) 2003-04-15
SK500172015A3 (en) 2002-07-02
SK288287B6 (en) 2015-07-01
CZ300364B6 (en) 2009-04-29
WO2001012812A2 (en) 2001-02-22
EA200200261A1 (en) 2002-08-29
BR0013391A (en) 2002-07-09
HK1043608A1 (en) 2002-09-20
KR20090016772A (en) 2009-02-17
DK1210425T4 (en) 2015-08-10
CA2383154C (en) 2013-04-30
US20120214687A1 (en) 2012-08-23
RS51157B (en) 2010-10-31
CN1379815A (en) 2002-11-13
DE60034579T3 (en) 2015-11-12
EP1210425B1 (en) 2007-04-25
NZ517782A (en) 2004-01-30
AU780240B2 (en) 2005-03-10
TR200201063T2 (en) 2002-10-21
US20200095305A1 (en) 2020-03-26
US20150139992A1 (en) 2015-05-21
NO20111232A1 (en) 2011-09-12
JP2011116790A (en) 2011-06-16
NO20020789D0 (en) 2002-02-18
GEP20053685B (en) 2005-12-12
SK2292002A3 (en) 2002-07-02
ATE360693T1 (en) 2007-05-15
DK1210425T3 (en) 2007-09-17
JP2011063600A (en) 2011-03-31
EP1806143A3 (en) 2007-07-18
US20020165156A1 (en) 2002-11-07
US7083785B2 (en) 2006-08-01
NO20020789L (en) 2002-04-08
JP2003507364A (en) 2003-02-25
HU1000128D0 (en) 2010-05-28
BRPI0013391B1 (en) 2018-09-11
KR20020084842A (en) 2002-11-11
EE05673B1 (en) 2013-08-15
EP2314694A2 (en) 2011-04-27
EP1210425B2 (en) 2015-06-17
US20100040627A1 (en) 2010-02-18
US9650430B2 (en) 2017-05-16
BG106519A (en) 2003-04-30
JP5379107B2 (en) 2013-12-25
US20020172674A1 (en) 2002-11-21
JP4787439B2 (en) 2011-10-05
HU227947B1 (en) 2012-06-28
IL148089A0 (en) 2002-09-12
UA75049C2 (en) 2006-03-15
US20180273605A1 (en) 2018-09-27
DE60034579D1 (en) 2007-06-06
PL211786B1 (en) 2012-06-29
EP1806143B1 (en) 2016-06-15
PL207501B1 (en) 2010-12-31
EA004635B1 (en) 2004-06-24
HUP0203084A2 (en) 2002-12-28
PL354661A1 (en) 2004-02-09
CA2383154A1 (en) 2001-02-22
AU6911200A (en) 2001-03-13
JP5904985B2 (en) 2016-04-20
EP2314694A3 (en) 2013-12-11
CZ2002579A3 (en) 2002-05-15
SK288603B6 (en) 2018-10-01
CN100447244C (en) 2008-12-31
IS6273A (en) 2002-02-15
US7691804B2 (en) 2010-04-06
HU230583B1 (en) 2017-02-28
IL230961A0 (en) 2014-03-31
DE60034579T2 (en) 2008-01-31
KR100897082B1 (en) 2009-05-14
YU10602A (en) 2005-06-10
MXPA02001665A (en) 2003-07-14
US8828669B2 (en) 2014-09-09
US10494416B2 (en) 2019-12-03
BRPI0013391B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
WO2001012812A3 (en) Baff receptor (bcma), an immunoregulatory agent
BG106670A (en) April receptor (bcma) and uses thereof
IL144578A0 (en) Antibodies specific to kdr and uses thereof
HUP0105283A3 (en) Baff, inhibitors thereof and their use in the modulation of b-cell response
PL366401A1 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
GB0019436D0 (en) Cross-linker monomer comprising double bond and photresist copolymer containing the same
AU3028900A (en) Ras activator nucleic acid molecules, polypeptides and methods of use
AU2002213021A1 (en) Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
WO2001083550A3 (en) Gpr22 modulators as appetite-control agents
AU2003235442A1 (en) 3-aza- and 1,4-diaza-bicyclo(4.3.0)nonanes, and methods of use thereof
AU2001263090A1 (en) Tnf and ifn stimulated genes and uses therefor
AU3355299A (en) Methods and apparatus for enhancing the capabilities of personal computers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-106/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148089

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/01201

Country of ref document: ZA

Ref document number: 200201201

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2292002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001665

Country of ref document: MX

Ref document number: PV2002-579

Country of ref document: CZ

Ref document number: 10077137

Country of ref document: US

Ref document number: 2383154

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027002098

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00216/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 69112/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 517782

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 106519

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000957502

Country of ref document: EP

Ref document number: 200200261

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 008142882

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002/01063

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: PV2002-579

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000957502

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027002098

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 517782

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517782

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 69112/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000957502

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 230961

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 500172015

Country of ref document: SK

Kind code of ref document: A